Clear gut bacteria clues for MS — what it means today

Credibility

Interest

Share:2 min read

Key Takeaway

Using careful, counts-based gut testing, researchers found consistent changes in the gut bacteria of people with MS that link to disease type, treatment response, and a marker of disease progression.

What They Found

The study used a method called quantitative microbiome profiling (QMP) that counts how many bacteria are in stool, not just which kinds are present. People with relapsing-remitting MS (RRMS) had fewer total gut bacteria, while people with primary progressive MS (PPMS) showed signs of slower gut transit (more watery stool measurements), which can change which microbes grow. After accounting for these and other confounding factors, the team found 21 groups of bacteria (genera) that were different in people with MS compared to controls. Looking across many previous studies, some commonly reported bacteria did not hold up, but higher amounts of certain microbes (for example, Akkermansia and Methanobrevibacter) and lower amounts of helpful butyrate-producing bacteria stood out as more reliable markers. The researchers also found that different gut community types (enterotypes) linked to treatment type and disease severity, and blood levels of GFAP (a protein that rises with brain tissue damage) were tied to specific gut bacteria in PPMS.

Who Should Care and Why

People with MS and their caregivers should care because this work points to gut bacteria patterns that could help explain why some people respond differently to treatments or have different disease courses — like how a garden’s soil affects which plants grow. Clinicians and care teams may use these findings to think about gut-focused strategies (diet, probiotics, or monitoring) as part of care, but only as complementary ideas for now. Patients on lower-efficacy disease-modifying therapies might notice a gut pattern linked to those treatments, suggesting gut checks could one day help guide treatment choices, similar to checking blood pressure before changing medicine. Caregivers can use this information to support diet and bowel-health habits, since gut transit time (how fast stool moves) can affect which bacteria thrive — like how moisture affects which plants sprout. Researchers will benefit because the study shows using absolute bacterial counts and controlling for stool moisture and other factors gives clearer, more reliable links than older methods.

Important Considerations

The study does not prove that the changed bacteria cause MS — it shows a link, not direct cause and effect. Some specific bacterial names and effects varied between datasets, and not all past findings were confirmed, so results should be seen as promising but not definitive. Also, gut tests and treatments based on these findings are not yet standard care, so discuss any changes with your healthcare team before trying new supplements or diets.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Early Research MS Genetics MS Diagnostics

Article Topics:

Multiple sclerosisbacteroides 2glial fibrillary acidic proteinmicrobiomequantitative microbiome profiling

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Gut microbes often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News